| Literature DB >> 18802090 |
Nadine Mothes-Luksch1, Sabine Stumvoll, Birgit Linhart, Margit Focke, Marie-Therese Krauth, Alexander Hauswirth, Peter Valent, Petra Verdino, Tea Pavkov, Walter Keller, Monika Grote, Rudolf Valenta.
Abstract
The recognition of conformational epitopes on respiratory allergens by IgE Abs is a key event in allergic inflammation. We report a molecular strategy for the conversion of allergens into vaccines with reduced allergenic activity, which is based on the reassembly of non-IgE-reactive fragments in the form of mosaic proteins. This evolution process is exemplified for timothy grass pollen-derived Phl p 2, a major allergen for more than 200 million allergic patients. In a first step, the allergen was disrupted into peptide fragments lacking IgE reactivity. cDNAs coding for these peptides were reassembled in altered order and expressed as a recombinant mosaic molecule. The mosaic molecule had lost the three-dimensional structure, the IgE reactivity, and allergenic activity of the wild-type allergen, but it induced high levels of allergen-specific IgG Abs upon immunization. These IgG Abs crossreacted with group 2 allergens from other grass species and inhibited allergic patients' IgE binding to the wild-type allergen. The mosaic strategy is a general strategy for the reduction of allergenic activity of protein allergens and can be used to convert harmful allergens into safe vaccines.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18802090 DOI: 10.4049/jimmunol.181.7.4864
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422